Drug Approval | May 03, 2025
USFDA inspection at Concord Biotech’s API facility at Dholka
These observations are procedural in nature and none of them are related to data integrity
These observations are procedural in nature and none of them are related to data integrity
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This significant milestone enhances our global regulatory standing
The Q1 2025 also witnessed a successful launch of Allegra D
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
